Background: Reported prolonged suppression of [ 11 C]raclopride binding potential (BP ND ) after amphetamine challenge suggested that physiological phasic discharges of dopamine (DA) during day-time could render DA D2/D3 receptors less accessible to [ 11 C]raclopride and cause decreased BP ND at night compared to morning hours. This hypothesis was tested in this study. Methods: Healthy middle-age subjects (41-65 years) were studied either in morning hours (8:30 AM; 56.1 ± 5.9 years; 5F/8M) or at night (9 PM; 53.8 ± 7.3 years; 8F/2M). Each subject had high-and lowspecific activity [ 11 C]raclopride scans (HSA and LSA) and one [ 11 C]methylphenidate (MP, a marker for DA transporter) scan. PET outcome variables, BP ND , the density of available D2/D3 receptors (B avail ), and the dissociation constant (K D ) were obtained by the bolus-plus-infusion transformation (BPIT) of bolus injection studies (JNM 2012) in limbic (ventral striatum; vS), associative (anterior putamen, aPu, and anterior and posterior caudate nucleus, aCN and pCN), and motor (posterior putamen, pPu) striatum which were defined on MRI. Results: Injected mass of raclopride were not different between morning (M) and night (N) groups for HSA (t = 1.2; p > 0.23) and LSA (M: 14.1 ± 5.8 mmol/mCi; Background: The endocannabinoid system regulates cognitive and emotional processes and pathology of this system is implicated in psychiatric disorders, including depression and schizophrenia. The precise Oral presentation abstracts S24
Indiana University School of Medicine, Indianapolis, Indiana, USA Background: The effects of oral and IV alcohol administration on striatal dopamine (DA) release have been studied in social drinkers, with equivocal results. However, the striatal DA system response to alcohol has not been studied in an alcoholic population. If alcoholics exhibit differential reactions of the DA system to alcohol, this could provide critical clues as to the neurobiological underpinnings of alcohol use disorders. Thus, the goals of this work were twofold: First, we sought to compare striatal DA responses to IV alcohol administration between nontreatment-seeking alcoholics (NTS) and social drinkers (SD). Second, we sought to determine the reproducibility of these effects. Methods: Twenty right-handed male smokers (10 NTS, 10 SD) were studied with PET and [ 11 C]raclopride (RAC) to determine the effects of IV alcohol on relative striatal DA levels. Subjects received two pairs of RAC scans (rest, IV alcohol) on two separate days. During the alcohol RAC scan, pharmacokinetic modeling was used to deliver an intravenous infusion of alcohol to a target blood alcohol concentration of 80 mg%. Results: No effects of IV alcohol on DA were found in SD on either Day 1 or Day 2, replicating our earlier findings in two other SD cohorts. In NTS subjects, IV alcohol resulted in reproducible increases in DA in the left anterior putamen, and reproducible decreases in DA in the right dorsal caudate. None of these effects were associated with either subjective responses to alcohol or alcohol craving. Conclusions: The distinctive anatomic pattern of DA responses to IV alcohol in currently-drinking alcoholics may be indicative of dopamine-related cogni-tive processes involved in hazardous drinking behavior, such as coding for stimulus salience and/ or habitual responding to the presence of alcohol.
Figure Reproducible effects of IV alcohol to intoxication (80 mg%) on striatal dopamine (DA) in nontreatment-seeking alcoholics (n = 10) on study Day 1 (left) and Day 2 (right). Voxel-wise testing was paired t-tests between BP ND from baseline and alcohol [ 11 C]raclopride scans on each respective study day. Voxels that met or exceeded display threshold of p < 0.05 (uncorrected) are shown in white. Top: Increases in DA in left anterior putamen. Bottom: Decreases in DA in the right dorsal caudate.
Background: Dopaminergic neurotransmission in the dorsal striatum is an essential component of the neural circuitry that mediates response inhibition. A recent animal study reports opposing roles for striatal D1-and D2-like receptors in response inhibition (1) . These findings suggest a model in which D1and D2-like receptors promote competing processes via modulation of the direct (go) and indirect (no-go) pathways, respectively (2) . Therefore, individual variation in striatal D1-or D2-like receptor availability may relate to individual response inhibition capacity. Despite known associations of D2-like receptors and response inhibition (3) , the relationship between D1-like receptors and response inhibition has not been tested. We hypothesized that individual differences in availability of both striatal D1-and D2-like receptors would be related to measurements of response-inhibition capacity. To test this hypothesis, we examined the relationship between performance on the Stop-signal task, a wellestablished test of response inhibition, and measurements of D1-and D2-like receptor availability using the PET radioligands 11 C-NNC-112 and 18 F-fallypride, respectively.
Methods: 15 healthy volunteers (8 men, mean age = 28.47, SD = 7.8) completed the stop-signal task and MRI scans. Nine participants underwent 11 C-NNC-112 PET scans for determination of caudate D1-like receptor binding potential (BP ND ) and twelve participants underwent 18 F-fallypride PET scans for determination of caudate D2-like BP ND . BP ND for each tracer was calculated using the Simplified Reference Tissue Model 2 (4) using the cerebellum as the reference region. Voxel-wise BP ND maps for each radiotracer were generated in standard space (MNI). Capacity for response inhibition was indexed by stop-signal reaction time (SSRT). Partial correlations were performed (controlling for age) to assess the relationship between BP ND and SSRT. Results: VOI analyses showed a significant correlation between caudate D2 BP ND for 18 F-fallypride and SSRT (r = -0.69, p = 0.019). However, D1 BP ND for 11 C-NNC-112 was not significantly correlated with SSRT. Exploratory voxel-wise regression analysis of 18 Ffallypride BP ND showed a negative relationship with SSRT in the dorsal striatum, at a liberal threshold due to small sample size (p < 0.05, uncorrected, Figure1). A similar voxel-wise regression analysis of 11 C-NNC- 112 BP ND showed a positive relationship with SSRT in a cortical area extending from the pre-supplementary motor area to the superior frontal gyrus, at the same liberal threshold (p < 0.05, uncorrected, Figure 1 ). Conclusions: Our results suggest that striatal D2-like receptors may contribute more than striatal D1-like receptors to the neurocircuitry of response inhibition. These results also provide preliminary evidence that D1-like receptors in the cortex play an important role in the neurocircuitry that underlies response inhibition. N: 16.3 ± 3.2 mmol/mCi; t = 1.2; p > 0.25) scans. B avail was greater for N than M group in pPu (22%) and vS (37%) (ANOVA: group effect: F = 4.75; p < 0.05; t-test: Figure Eadie-Hofstee plot showing DA receptors that were occupied by DA in morning (B M ) and at night (B N ). B avail is given by B max -B M or B max -B N for morning or at night. p = 0.012 vS; p < 0.05 for pPu). Baseline BP ND of [ 11 C]raclopride (group effect: F = 2.20; p = 0.147) and [ 11 C]MP (F = 0.25; p = 0.62), and K D (F = 1.95; p = 0.173) remained unchanged between groups. To understand the findings, the Eadie-Hofstee plot (x: bound/free; y: bound; y-intercept: B max (the receptor density); and slope: -K D ) was extended to include bound DA receptors for groups N ( = B N ) and M (=B M ) as shown.
Conclusions: Contrary to the hypothesis, B avail were higher at night than morning without changes in K D . The Eadie-Hofstee plot indicates that, to achieve observed increases in B avail ( = B max -B M or B max -B N for M and N groups), occupancy of DA receptors in morning must be greater than 18% for pPu and 27% for vS. Therefore, this model suggested that baseline occupancy of D2/D3 receptors by DA could be higher than commonly assumed (i.e., 10%).
O4. The relation between body mass index and dopamine D2 receptor availability in the caudate: a PET study in humans (Figure) in one-pot sequences at high specific activities. Upon HPLC purification, the formulated radiotracers were administered to SD rats via tail-vein and animals sacrificed at 2 and 40 mins post-injection. Brain regions were excised and counted for radioactivity. Blocking studies to determine specificity of binding were performed by pre-treatment with the FAAH classical inhibitor URB 597. For select radiotracers, the kinetics of in vivo irreversible binding were determined by brain homogenization techniques.
Results: All eight of the novel and potent radiotracers were synthesized in high radiochemical purities ( > 97%) and with high specific activities (1500-5000 mCi/mmole). After iv injections to rats, moderate to high brain penetration was observed with SUVs from 0.8 to 4 at 40 min post injection. While there is no brain region devoid of FAAH, in all cases the FAAH-rich cortex displayed higher uptake than the FAAH-poor hypothalamus. Specific binding to FAAH represented 75-90% of total binding as determined by pre-treatment with URB 597 (2 mg/kg ip). Specific binding of the radiotracers to FAAH was irreversible as shown by brain homogenate studies but the rate of binding varied considerably.
Conclusions: Several of the novel carbon-11 radiotracers described here have considerable potential for imaging FAAH with PET. They displayed high brain uptake, appropriate regional distribution, and specificity for FAAH. Having radiotracers with a range of binding kinetics will be useful in designing the optimal radiotracer in human FAAH imaging studies.
Background: The metabotropic glutamate receptor subtype 2 (mGluR2) is widely distributed in brain including cerebral cortex, cerebellum, and subcortical structures. The receptor is predominantly presynaptic and modulates the release of glutamate through feedback inhibition. Orthosteric agonists for group 2 mGluRs have been identified and have shown beneficial effects in a variety of preclinical behavioral models and clinical conditions including anxiety and schizophrenia. Recently, positive allosteric modulators (PAMs) of the mGluR2 have been developed as a potentially more selective and nuanced approach to enhancing mGluR2 function. The location of the allosteric site or sites on the receptor is not known but is not identical with the agonist binding site and chemotypes for candidate mGluR2 PAMs are quite different from the scaffold typical of orthosteric ligands. [ 11 C]JNJ-42491293 has been identified as a candidate PET tracer for an mGlu2 allosteric site. Preclinical studies of [ 11 C]JNJ-42491293 indicate high affinity (IC50 = 9.6 nM) and selectivity of the tracer for the human mGluR2, and showed that in vivo binding is reversible and displaceable by compounds targeting this allosteric site. As such, it can be used for profiling the distribution of the mGluR2 in human in vivo and may be useful for testing target engagement and dose occupancy of clinical leads with affinity for the same site. The safety, biodistribution, dosimetry, and kinetic modeling of [ 11 C] JNJ-42491293 was determined in humans in preparation for possible occupancy studies. Methods: Studies were conducted in 20 healthy male subjects (age range 19-35 y) on a Siemens HiRez 16 slice LSO PET/CT camera. Biodistribution and radiation burden was determined in the first 3 subjects using dynamic whole-body PET-CT. Effective doses were calculated with OLINDA based on image-derived source organ residence times. Dynamic brain scans were acquired over 90 minutes from time of injection in the subsequent 17 healthy volunteers along with arterial and venous sampling and metabolite determination. Regional tissue distribution and tissue and blood kinetics of the tracer were analyzed using PMOD. Safety and tolerability were assessed. Results: [ 11 C]JNJ-42491293 was readily taken up in the brain, with maximum activity around 30 minutes in grey matter followed by uniform decline. Retention in grey matter relative to white matter was similar throughout cortex, and was higher in striatum and cerebellum, consistent with reported distribution of the mGluR2 in brain. The tracer appeared to be retained in striate muscle including the heart, consistent with the reported expression profile for mGluR2. imaging studies were performed in rhesus monkeys using the Focus-220 scanner. Arterial input functions were generated for each scan. Metabolite analysis was performed with HPLC. Plasma free fraction was determined by ultrafiltration. Imaging data were analyzed with compartment models and the simplified reference tissue model (SRTM) with cerebellum as reference.
Results: F3PB displayed high in vitro binding affinity and selectivity for the kappa opioid receptor.
(Ki of 0.18, 7.68, and 91.3 nM, respectively, for k, m, and d receptor). [ 11 C]F3PB was prepared in > 95% radiochemical purity and mean radiochemical yield of 10.7% (EOS, n = 7). [ 11 C]F3PB was metabolized fairly quickly. At 30 min following tracer injection, parent fraction in the plasma was B20%. Plasma free fraction was 4.3 ± 0.4% (n = 7). In the monkey brain, it displayed fast uptake kinetics, with regional activity peaked at B10 min post-injection. Regional time-activity curves were well described with the 2-tissue compartment model and SRTM. Mean regional binding potential (BP ND ) values from SRTM analysis were 2.15, 1.32, 1.07, 1.05, and 0,6, respectively, for the globus pallidus, cingulate cortex, putamen, caudate and frontal cortex (n = 3). Specific binding was completely blocked by pretreatment with naloxone (1 mg/kg, iv, n = 2) and dose-dependently by the selective KOR antagonist LY2456302 (various dose).
Conclusions: [ 11 C]F3PB demonstrates favorable properties as a PET radiotracer for in vivo imaging of the kappa opioid receptor. An added advantage of this tracer is that it can be labeled with the longer-lived isotope F-18, whose preparation and evaluation is currently underway.
O8. [ 11 C]Elacridar, a PET radiotracer to measure the function of P-glycoprotein and breast cancer resistance protein at the blood-brain barrier: first assessment in healthy human subjects Background: The multidrug efflux transporters P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) form a concerted defence mechanism at the blood-brain barrier (BBB) where they restrict the brain distribution of several clinically used drugs. Animal studies have demonstrated that [ 11 C]elacridar is a dual substrate of Pgp and BCRP, which shows a low degree of in vivo metabolism and which lacks brain uptake of radiolabeled metabolites. 1 The aim of this study was to perform an initial evaluation of [ 11 C]elacridar in healthy humans subjects as a potential PET radiotracer to measure Pgp and BCRP function at the human BBB. Methods: In 4 healthy subjects dynamic [ 11 C]elacridar brain PET scans and arterial blood sampling were performed over 120 min. At 60 min after injection of [ 11 C]elacridar, subjects received an i.v. infusion of the potent Pgp inhibitor tariquidar (AzaTrius Pharmaceuticals Pvt. Ltd., London, UK) at a dose of 3 mg/kg body weight over 30 min. Radiolabeled metabolites of [ 11 C]elacridar in plasma were measured with a solid-phase extraction/HPLC assay. Brain activity uptake was expressed as the ratio of the area under the whole brain grey matter time-activity curve to the area under the plasma time-activity curve from time 0 to 60 min (AUC 0-60 brain /AUC 0-60 plasma ). In 4 additional subjects whole body PET/CT scans were acquired over 100 min. Results: Brain activity uptake was low after injection of [ 11 C]elacridar with a mean AUC 0-60 brain / AUC 0-60 plasma of 0.13±0.03. No change in whole brain time-activity curves was observed during or after tariquidar infusion (Figure 1 ). At 60 min after radiotracer injection, 86±5% of total radioactivity in arterial plasma was in the form of unchanged parent radiotracer. Whole body scans showed that [ 11 C]elacridar was mainly excreted via the hepatobiliary route. The estimated total effective dose was 2.8 mSv/MBq.
Conclusions: Low brain uptake in humans was consistent with [ 11 C]elacridar being a dual substrate of Pgp and BCRP. In a previous human PET study with the Pgp substrate radiotracer (R)-[ 11 C]verapamil we have observed a pronounced increase in brain timeactivity curves in response to tariquidar infusion. 2 This effect was not observed in the present study with [ 11 C]elacridar, in all likelihood because tariquidar preferentially blocked Pgp at the studied dose and [ 11 C]elacridar was still actively effluxed by BCRP at the BBB. [ 11 C]Elacridar may be a useful radiotracer to study Pgp and BCRP function at the human BBB.
Background: To increase our understanding of the role of microglia in neurological disorders animal models are of great value. Small animal PET allows for studying microglia activation in these models longitudinally, using radioligands that bind to the translocator protein (TSPO). There are however methodological challenges for quantification of this receptor and, consequently, microglia activation. There is no suitable reference region and the use of plasma-derived input is not an option for longitudinal studies. The aim of this study was therefore to evaluate the use of the semi-quantitative standardized uptake value (SUV) as an outcome measure in small animal PET studies on microglia activation for the TSPO ligand [ 11 C]PBR28 [1] . In addition, the test-retest variability of the SUV was determined.
Methods: Healthy male Wistar rats (n = 8, 363 ± 57 grams) were divided in two groups. The first group (n = 4) was used to determine the correlation between the distribution volume (V T ) obtained by Logan graphical analysis and the SUV (t = 57-63 min after injection). In the second group (n = 4) the test-retest variability of the SUV (t = 57-63 min) was determined, with a 7-day interval between scans. Dynamic PET scans of 63 minutes were acquired after injection of 23 ± 5 MBq [ 11 C]PBR28, with the nanoScans PET/MRI (Mediso Ltd, Budapest, Hungary [2] ). An MRI scan was made for anatomical reference. For the first group arterial blood samples (n = 16) were taken during the scan for radioactivity measurements in blood and plasma, as well as radiometabolite analysis (n = 3). Results: The brain uptake of [ 11 C]PBR28 was highest at 1 minute after injection and reached a steady state at 45 minutes. [ 11 C]PBR28 in blood and plasma peaked at 10-15 seconds after injection. Radiometabolite analysis showed that at 4 minutes after injection 43±10% of the total radioactivity in plasma was [ 11 C]PBR28, which was reduced to 4 ± 3% at 60 minutes. The time-activity curves of 9 different regions were fitted with Logan graphical analysis, using radiometabolite corrected plasma input. The whole brain V T was 43.1 ± 1.2. The highest V T was found in the cerebellum (54.0 ± 1.9), whereas the thalamus had the lowest V T (34.2 ± 2.7). A statistical significant correlation (r 2 = 0.95; p < 0.0001) was found between the V T and the SUV (0.63±0.05 for whole brain). The whole brain uptake of [ 11 C]PBR28 in the testretest study (average SUV 0.49±0.07) showed an intersubject variability of 14.3% and a retest variability of 13.6%. The interclass correlation coefficient (ICC) was 0.59, showing that the variability is higher between than within rats. Similar or higher ICC values (0.58-0.88) were found for the other brain areas, with exception of the cortex (0.33).
Conclusions: The SUV of [ 11 C]PBR28 showed a high correlation with the V T as obtained by Logan graphical analysis, as well as a good test-retest variability. For future longitudinal small animal PET studies the SUV can thus be used to describe [ 11 C]PBR28 uptake in healthy brain tissue. Background: The second generation radioligand for the 18 kDa translocator protein (TSPO), [ 11 C]PBR28, has greater specific-to-nonspecific binding than the prototypical radioligand [ 11 C](R)-PK 11195. However, TSPO shows differential affinity for [ 11 C]PBR28 and similar radioligands in human studies, likely caused by the TSPO Ala147Thr polymorphism. We sought to determine if 1) TSPO genotype correlates with PBR28 binding both in vitro and in vivo, 2) differential affinity of PBR28 exists in both control and schizophrenia brain tissue, and 3) stratifying subjects by genotype could increase statistical power of [ 11 C]PBR28 to detect group differences in TSPO density in a hypothetical clinical study. Background: It is well documented that neuroinflammation may play an important role in neurodegeneration in Parkinson's disease (PD). Post-mortem studies have confirmed the presence of reactive microglia and astrocytes. Previous PET imaging studies also reported a possible role of neuroinflammation in PD. Here, we used a recently developed PET radioligand, [ 18 F]FEP-PA, binding to the translocator protein (TSPO) to measure level of microglial activation in PD. Methods: Nine PD patients and twelve age-matched healthy controls underwent a [ 18 F]FEPPA PET and MRI scan. Arterial plasma sampling and metabolite analysis were performed to create plasma input curves. A 2-compartment model analysis was applied and total distribution volume (V T ) was calculated in each regionof-interest (ROI) delineated by fully automated procedure. Student t-test is used to test the difference between the PD patients and controls.
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Results: PD patients showed significantly higher [ 18 F]FEPPA V T in the striatum, particularly the left putamen (PD: 11.1 ± 1.77 vs. controls: 7.45 ± 0.73; p < 0.05) and left caudate (PD: 9.42±1.21 vs. controls: 5.46±0.67; p < 0.05). The TSPO expression was also elevated in the thalamus (PD: 13.5 ± 1.42 vs. controls: 9.85 ± 0.94; p < 0.05).
Conclusions:
The subcortical increase of [ 18 F]FEPPA V T suggests that microglia activation is significantly elevated in PD. This tracer may provide a valuable in vivo evaluation of neuroinflammation's role in PD. Background: The endocannabinoid system plays a pivotal role, through the CB1 receptor, in regulating food intake and energy expenditure. It has been shown that CB1 receptor antagonists/inverse agonists not only inhibit food intake and reduce body weight in animals and humans but also directly modulate fat metabolism at peripheral sites in skeletal muscle, adipose tissue, and the liver. Although the first generation CB1 antagonists such as rimonabant and taranabant showed clinical efficacy, they showed severe CNS side effects such as anxiety, depression and suicidal ideation. To eradicate such CNS side effects, compounds with a profile of restriction to peripheral CB1 receptors have been developed. In this PET study, we investigated the brain CB1 receptor occupancy of a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates. An autoradiographic blocking study was also performed using postmortem human and non human primate brains. Methods: Two cynomolgus monkeys were used in the PET study. PET measurements were performed for 120 min with High Resolution Research Tomograph (HRRT) (Siemens) after injection of [ 11 C]MeP-PEP at baseline and at pretreatment conditions. Pretreatment was by intravenous administration at dose levels of 0.3-4.0 mg/kg of bolus injection and 3.0 mg/kg of bolus plus 3.0 mg/kg/hr of infusion for TM38837 and 0.3-3.0 mg/kg of bolus injection for rimonabant. Brain CB1 receptor binding was calculated using average SUV at late time based on the previous quantitative report [1] . Brain CB1 receptor occupancy was calculated with the difference of SUV values at baseline and at pretreatment conditions using Lassen plot. Relationship between brain CB1 receptor occupancy and dose/plasma concentration were evaluated with hyperbolic functions. Kd values, at which 50% of CB1 receptor was occupied, were calculated. In the autoradiography study, the blocking effect to [ 125 I]SD7015 accumulation by TM38837 (10 mM) and rimoabant (10 mM) was evaluated using postmortem human and non-human primate brain slices. Results: CB1 receptor occupancy by both TM38837 and rimonabant increased in a dose/plasma concentration dependent manner. However, Kd values for dose was found to be approximately 10 times higher in TM38837, and Kd values for plasma concentration was found to be more than 100 times higher for TM38837, which indicated much lower CNS penetration of TM38837. In autoradiography study, [ 125 I]SD7015 accumulation was blocked by both TM38837 and rimonabant, which indicated that both have high affinity to CB1 receptor. Conclusions: Only low levels of brain CB1 receptor was demonstrated to be occupied by TM38837 although TM38837 has high affinity to CB1 receptor. This low CNS penetration of TM38837 could lead to low incidences of CNS side effects at clinical situations. The present study warrants further development to clinical application.
O13. Low brain CB1 receptor occupancy by a second generation CB1 antagonist TM38837 in comparison with rimonabant in nonhuman primates
O14. The use of [ 11 C]OMAR and positron emission tomography to investigate the pathophysiology of posttraumatic stress disorder Background: Recent preclinical and clinical evidence suggests that disruptions in CB1 receptor-mediated endocannabinoid (eCB) signaling may contribute to the neurobehavioral changes initiated by trauma exposure, and prohibit proper extinction of aversive memories in a cortico-limbic-striatal circuit that has been implicated in posttraumatic stress disorder (PTSD). The recent development of the CB1 receptor selective radiotracer, designated [ 11 C]OMAR now makes it possible for the first time to conduct an in vivo assessment of CB1 receptor density in PTSD using positron emission tomography (PET). Methods: Using [ 11 C]OMAR and PET on a high resolution research tomograph (HRRT) PET scanner, we determined volume of distribution (VT) values, a measure of CB1 receptor density, under resting conditions in medication-free PTSD patients (N = 16/ 8F, age, ys 30.0 ± 8.5, range 20-44, CAPS 78 ± 11.5), individually-matched healthy control subjects (N = 16/ 8F, age, ys 30.6±7.5, range 20-45). Following a transmission scan, [ 11 C]OMAR was injected over one min and HRRT list mode data was acquired for 120 minutes. Dynamic scan data was reconstructed with the following corrections: attenuation, normalization, scatter, randoms, and deadtime. Motion correction of PET data was performed via frame-byframe registration to a summed image (0-10 min post injection). A new summed image was then created from the motion-corrected data and registered to the participant's T1-weighted MR images, which, in turn, were registered to an MR template. Gray matter regions of interest are taken from the template (Anatomical Automatic Labeling (AAL) for SPM2) and applied to the PET data to produce time-activity curves for relevant regions of interest (ROI) and control regions. Arterial plasma input functions were measured and a range of analysis methods were used to estimate volume of distribution (VT) from regional time activity curves (TACs). Blocking studies using unlabeled OMAR in non-human primates show that in animals the specific binding component is about 1-1.5 relative to the non-specific binding component. Assuming there is no species difference we assume that this ratio is the same in our population. Data were analyzed using linear mixed models with [ 11 C]OMAR VT as the dependent variable, region (Amygdala, Hippocampus, Anterior Cingulate, Posterior Cingulate, Caudate, Putamen, Pallidum) as within-subject factor and diagnosis and gender as between-subject factors. Results: We found elevated CB1 binding in PTSD relative to the healthy control subjects in all regions of the aforementioned PTSD circuit (F(1,28) = 12, p < .0017) (Percent Difference PTSD vs HC, Amygdala: 29.6, ACC: 25.6, PCC: 26.1, caudate: 27.6, hippocampus: 26.2, pallidum: 31.1, putamen: 24.4). Independent of diagnosis, we found significantly higher CB1 binding in women relative to men (F(1,28) = 9.88, p < .0039). Conclusions: Our data show that the maladaptive neurobehavioral trauma response in PTSD is associated with impaired eCB signaling as evidenced by upregulation of CB1 receptors. In addition, we found evidence for gender differences in CB1 receptor denisty in both PTSD and healthy people.
role of the endocannabinoid system in psychiatric disorders remains unclear, but changes in expression of CB 1 receptors and subsequent altered modulation of monoamines is suggested in depression (Esteban & García-Sevilla, 2011). CB 1 receptor agonists, such as WIN55,212-2 and CP55,940 regulate synthesis and release of monoamines and are suggested as a novel therapy in the treatment of depression. However, further studies are needed to identify the precise mechanisms of action and pathology of the endocannabinoid system in depression. The hypothesis that depressive-like traits are related to altered CB 1 receptor expression were tested in in-vitro autoradiography experiments, measuring binding of [ 3 H]OMAR, a highly selective CB 1 receptor antagonist (Horti et al, 2006) in the Flinders rodent model of depression. Figure 1 ). In refutation of the hypothesis, these estimates of [ 3 H]OMAR binding in FSL and FRL rats were not significantly different.
Conclusions:
Although changes in CB 1 receptor expression have been demonstrated in human suicide victims with depression and in animal models of depression, the present maps of [ 3 H]OMAR binding revealed no difference between FSL and FRL rats. We used a single concentration of [ 3 H]OMAR in this study. In future studies with several concentrations of [ 3 H]OMAR, we will test the hypothesis that depression-like behavior of FSL rats is related to changes of the kinetic Michaelis constants K d and B max of CB 1 binding.
Background: Brain cannabinoid CB 1 receptors contribute to alcohol-related behaviors in experimental animals. Chronic alcohol exposure decreases the density of CB 1 receptors in rodents, and a postmortem study recently found decreased CB 1 receptor density in the ventral striatum of human patients with alcohol dependence. A common single nucleotide polymorphism in the CB 1 receptor gene, rs2023239, is associated with alcohol dependence in the population and higher density of CB 1 receptor in vitro. Whether cannabinoid CB 1 receptors are decreased in vivo in human subjects with alcohol dependence and whether rs2023239 modulates CB 1 receptors in vivo is unknown. Methods: We measured CB 1 receptors in alcohol dependent patients (aged 44 ± 10 years, 5-50 years of alcohol use) in early and protracted abstinence, and in comparison with control subjects with no alcoholuse disorders (aged 44 ± 10 years). We used positron emission tomography (PET) and [ 18 F]FMPEP-d 2 , a radioligand for CB 1 receptors. We scanned 18 male inpatients with alcohol dependence twice, within 3-7 days of admission from ongoing drinking, and after 2-4 weeks of supervised abstinence. Imaging data were compared with those from 19 age-matched healthy male subjects without alcohol use disorders. Data were also analyzed for potential influence of the common functional variation rs2023239 in the CB 1 receptor gene. Arterial blood was sampled during PET scans to estimate receptor binding as distribution volume (V T ), which is the ratio at equilibrium of the concentration of radioactivity in brain to that of the parent radioligand in plasma. Results: On the first scan, V T of [ 18 F]FMPEP-d 2 was 20-30% lower in patients with alcohol dependence than in control subjects in all brain regions and was negatively correlated with years of alcohol abuse but not with measures of withdrawal or craving. This decrease was not confounded by cigarette smoking. The plasma free fraction of [ 18 F]FMPEP-d 2 was not lower in patients with alcohol dependence (0.4± 0.1%) than in healthy subjects (0.4±0.2%), and therefore did not cause reduction in V T . After 2-4 weeks of abstinence, V T of [ 18 F]FMPEP-d 2 did not change and, thus, remained similarly reduced in these patients. Irrespective of diagnostic status, C allele carriers at rs2023239 had higher V T compared to non-carriers, consistent with a previous in vitro study. Conclusions: Alcohol dependence is associated with a widespread reduction of cannabinoid CB 1 receptor binding in the human brain and this reduction persists at least 2-4 weeks into abstinence. The correlation of reduced binding with years of alcohol use suggests an involvement of CB 1 receptors in alcohol dependence in humans. In a direct in vivo correlate of in vitro ligand binding data, carriers of the C allele of the rs2023239 variant had higher CB 1 binding than non-carriers.
O17. PET imaging of the excitatory amino acid transporter 2 in an amyotrophic lateral sclerosis rat model
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Background: Excitatory amino acid transporter 2 (EAAT2) found on CNS astrocytes is the primary mechanism for clearance of extracellular levels of L-glutamate (L-Glu). Excitotoxic injury promoted by elevated L-Glu can be a result from altered regional EAAT2 activity and/or cell surface expression. Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder marked by the progressive loss of motor neurons in the spinal cord, brain stem and motor cortex. Excessive L-Glu levels and decreased EAAT2 profiles constitute a mechanism that contributes to neuronal loss (1). ALS postmortem CNS tissue studies of L-Glu uptake into synaptosomes have revealed EAAT2 is markedly reduced. Similar focal EAAT2 losses are found in CNS tissues taken from a superoxide dismutase1 (SOD1) G93A mutant rat model that presents ALS-like symptoms and pathology (1-3). We have identified a novel EAAT2 fluorine-18 PET imaging prodrug tracer, 1, that undergoes CNS hydrolysis affording the high EAAT2 affinity radioligand 2 the capability of detecting EAAT2 in wild type (WT) rats by microPET imaging. We posit that regional CNS PET imaging of EAAT2 will quantify regional alterations in EAAT2 in ALS. To initially test this hypothesis we used tracer 1 and performed a comparative longitudinal evaluation of G93A SOD1 rats relative to WT subjects. Methods: A G93A rat cohort was established in parallel to littermate WT controls. A cohort portion (n = 3) underwent PET imaging at three progressive times occurring from symptom onset through late stage sacrifice. An electrophilic radiosynthesis afforded tracer 1. Spine and brain PET scans were acquired with an Inveon DPET scanner, 0-90 min; i.v. tail vein. PET data were co-registered to MR scans (Bruker Biospec 7T spectrometer). The non-imaged cohort balance was sacrificed per the scans days, and then brain and spine tissues were collected for ex vivo analyses. Results: Administration of 1 ( > 95% purity; mean SA 2.3 Ci/mmol, n = 20) resulted in high radioactivity uptake in spine (lumbar) and brain (thalamus, cortex, and other ROIs) consistent with known EAAT2 densities (1) . PET imaging of the G93A mutants vs. WT controls showed significant progressive reductions of EAAT2. Mutant PET data normalized to WT profiles revealed time dependent EAAT2 decreases akin to similar longitudinal determinations made previously by others quantifying L-Glu uptake into synaptosomes prepared from rat CNS postmortem tissue (3). Conclusions: Prodrug 1 undergoes hydrolysis to radioligand 2 in the rat CNS allowing binding to and detection of EAAT2 by microPET imaging. Progressive reductions of EAAT2 in G93A SOD1 mutants as a function of pathological development are consistent with correlated postmortem tissue blot evaluations and previously described EAAT2 changes determined by synaptosome L-Glu uptake assays. The active radioligand 2 quantitatively detects progressive CNS EAAT2 changes in the rat ALS model, warranting the further development of tracer 1.
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Background: The ability to detect changes in receptor binding at the metabotropic glutamate receptor 5 (mGluR5) could be valuable for elucidating dysfunctional glutamate transmission associated with neuropsychiatric illnesses. A recent study performed in baboons reported a significant global decrease in binding of [ 11 C]ABP688, an mGluR5 imaging probe, after administration of N-acetylcysteine (NAC), a facilitator of glutamate release [1] . NAC, a precursor of cysteine, indirectly increases extrasynaptic glutamate via the cysteine-glutamate antiporter, which then stimulates metabotropic glutamate receptors to modulate synaptic glutamate neurotransmission [2, 3] . The aim of our study was to replicate the aforementioned study in rhesus monkeys. Methods: Paired scans were performed in rhesus monkeys on the Focus-220 with [ 11 C]ABP688. Each monkey (n = 3) received a baseline scan followed by a challenge scan. NAC (50 mg/kg) was infused for an hour prior to the second tracer injection. In one pair of baseline/blocking scans, [ 11 C]ABP688 was administered as a bolus/infusion (B/I, K bol = 60 min), followed by 120-min emission acquisitions. In the other two pairs of scans, [ 11 C]ABP688 was administered as a bolus followed by 90-min emission acquisitions. Listmode data were reconstructed with FBP with all corrections (attenuation, normalization, scatter, randoms, and deadtime). Time-activity curves (TACs) were generated for regions-of-interest (ROIs), derived from a nonlinear monkey template. V T values were computed via equilibrium analysis for the B/I scans, where V T = C ROI /C Plasma , using the concentration (C) in the ROIs and the plasma between 30-80 min. For the bolus scans, TACs were fitted with a two-tissue compartmental model to estimate V T . The cerebellum gray matter (CGM) was used as the reference region to compute BP ND , where BP ND = V T (ROI)/V T (CGM)-1. Percent change in BP ND was computed as DBP ND = (BP ND (Post)/BP ND (Baseline)À1)*100 and was averaged across studies. Results: NAC did not significantly decrease [ 11 C]ABP688 BP ND from baseline: cingulate (-4 ± 13%), occipital (-7 ± 21%), frontal (-6 ± 13%), temporal (-2±9%), caudate (-2±11%), and putamen ( + 2± 26%). No significant change was observed in V T for the CGM reference region ( + 3 ± 11%). Background: We report the kinetic analysis of [ 11 C]JNJ42491293, a PET ligand for in vivo imaging of mGluR2 in the human brain, binding with highaffinity (hIC50 = 9.6 nM) and reversibly to the allosteric binding site. This tracer has been developed to confirm target engagement and define exposureoccupancy relationships of clinical candidates targeting this site. Methods: 17 male subjects (age range 19-35y) were intravenously injected with 323 + /-30 MBq [ 11 C]JNJ42491293 in bolus. Starting at injection, baseline dynamic brain PET was performed for 120 min on a Siemens Biograph Hirez 16 slice PET/ CT system. Blood samples were taken during the PET scan to generate an input function and to allow metabolite analysis. A triple exponential function was fitted to the plasma data, while a Watabe function [1] was fitted to the parent fraction. Dynamic PET data were reconstructed using iterative reconstructions (5 iterations, 8 subsets, 5 mm Gaussian post filter). Images were analyzed using PMOD 3.1. An average PET image was registered to the corresponding individual MR; followed by a nonlinear normalization of the MR data to a T1 weighted MR template. VOIs were predefined for cortical (orbitofrontal, frontal, parietal, temporal, hippocampus, occipital), subcortical (caudate nucleus, putamen, thalamus) and brainstem regions (pons and medulla) as well as cerebellum. TACs were generated for the different VOIs. A 2 tissue (2T) compartment model, 1 tissue (1T) compartment model and Logan graphical analysis were considered for kinetic analysis using an arterial input function corrected for metabolites. For the 1T and 2T compartment models, parameters were initially estimated for the whole brain compartment and then adjusted for each VOI. For the 2T compartment, distribution volume V ND for non-specific binding was assumed constant for all cortical and subcortical regions. Results: Distribution volumes of the 2T compartment model and Logan graphical analysis were well correlated for all regions (see Figure 1 ). For the 2T compartment model, total distribution volume V T and the distribution volume for specific binding for the whole brain V S were linearly correlated, indicating a nearly constant value for non-specific distribution volume V ND of 1.16 (see Figure 2) . A 1T compartment model was not better than a 2T model, based on the Akaike Information Criterion (AIC) [2] in all but one dataset (see Figure 3 ). Conclusions: Baseline dynamic brain PET in healthy volunteers indicate that the tracer kinetics of [ 11 C]JNJ42491293 in the human brain can be analyzed by a 2 tissue compartment model or by Logan plot, providing estimates of V T . Background: We have shown that patients with major depressive disorder who do not remit (nonremitters) to selective serotonin reuptake inhibitors (SSRIs) have lower 5HT 1A binding in regions such as the amygdala and hippocampus than those who do (remitters). This decrease in 5HT 1A binding may be due to either a diminished number of serotonergic fibers (originating from the raphe in the midbrain) or reduced 5HT 1A expression. These possibilities can be examined using Diffusion Tensor Imaging (DTI), which identifies fiber tracts between regions by measuring the diffusion of water molecules in the brain [1] . Fractional anisotropy (FA), a DTI-derived measure of the lack of free diffusion of water, can then be used as an index of the health of the identified tracts [1] . Methods: Eighteen subjects with major depressive disorder received 25-direction DTI and Positron Emission Tomography (PET) scans prior to 65±11 days of treatment with an SSRI. Severity of depression was assessed with the 24-item Hamilton Depression Rating Scale (HDRS) before and after treatment, with remission defined a priori as a 50% decrease in HDRS and a final score r10. Raphe nuclei were extracted from the [ 11 C]-WAY-100635 PET image [2] and included within a midbrain region of interest. Probabilistic tractography was performed between the midbrain (seed) and the amygdala or hippocampus (targets) (see Figure 1 ). Average FA values, which range from 0 to 1, were calculated by taking the mean of voxel FA values within the defined fiber tracts, weighted by the number of fibers crossing through that voxel.
Conclusions: Changes in mGluR5 BP
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Results: Average FA in fiber tracts to the right amygdala target was significantly lower in nonremitters (0.51 ± 0.05) versus remitters (0.58 ± 0.05, p < 0.01). At a trend level, both the number of tracts to the amygdala targets (p = 0.13, right, p = 0.08, left) and the average FA in tracts to the left amygdala target (p = 0.16) were also lower in non-remitters. No significant differences were found in average FA values, or number of tracts, to the right or left hippocampus target.
Conclusions: These results suggest that the health and/or number of serotonergic fibers terminating at the amygdala may be compromised in SSRI non-remitters. Moreover, since these differences were not observed in tracts terminating at the hippocampus, this effect may be regional. Future studies are needed to confirm this relationship in a larger cohort, examine these findings in healthy volunteers, and determine whether treatment affects this abnormality. Background: Recent mathematical models suggest that restored serotonergic bursts underlie the antidepressant effect of selective serotonin reuptake inhibitors (SSRI) [1, 2] . Burst recovery is tuned to a downregulation of serotonin transporter (SERT) availability in terminal regions and this may highly depend on the interregional balance between SERT availability in the raphe nuclei and in terminal regions before treatment.
O22. Treatment response in major depression predicted by serotonin transporter interplay
To evaluate this in humans, we investigated SERT availability and occupancy longitudinally in patients with major depressive disorder.
Methods: Using positron emission tomography (PET) and the radioligand [ 11 C]DASB, measurements were performed before and after a single oral dose, as well as after three weeks (mean 24.73 ± 3.3 days) of continuous oral treatment with either escitalopram (10 mg/day) or citalopram (20 mg/day). Data were analyzed using voxel-wise linear regression and ANOVA to compare SERT binding and binding ratios.
Results: Brain areas showing significant differences (ANOVA) between responders and non-responders and between remitters and non-responders for SERT BP ND ratios (SERT BP ND in the whole brain normalized to SERT BP ND in the median raphe nucleus) are given in Figure A . Regression analyses revealed that lowered SERT availability in the median raphe compared to SERT availability in key regions for depression such as the habenula, amygdala-hippocampus complex, and subgenual cingulate cortex highly predicted the antidepressant response (see Figure B) . Conclusions: Our data provide a first proof-ofconcept for recent modeling studies and further underlie the importance of the habenula and subgenual cingulate cortex in the etiology of and recovery from major depression [3] . These findings may indicate a promising molecular predictor of treatment response and stimulate new treatment approaches based on regional differences in SERT binding.
O23. PET imaging of serotonin transporter in monkeys: effects of maternal separation, and long-term fluoxetine treatment during adolescence Background: Major depressive disorder (MDD) is a serious disorder that often begins following stress during adolescence. Selective serotonin reuptake inhibitors (SSRIs) are a common treatment for both adolescent and adult MDD. While MDD's early onset and available efficacy data support use of SSRIs in adolescents, concerns about safety have arisen, based on associations with suicidal behavior in adolescents, coupled with minimal data on long-term effects on the developing brain. This study used rhesus monkeys as a model to study the long term effects of both early life stress and chronic antidepressant treatment during adolescence (2-year of age) on the serotonin transporter. Methods: Thirty-two monkeys were randomly assigned to one of four groups (8 monkeys/group). They were peer-reared (PR) vs. mother-reared (MR), and with or without fluoxetine treatment. For PR, monkeys were separated from mothers at birth and nursery-reared until 6 months of age and thereafter housed with their peers. Chronic fluoxetine treatment began at 2-year of age for one year. One to two years post-washout, monkeys (average age of 5) were scanned with Positron Emission Tomography (PET) using [11C]DASB for serotonin transporter (SERT). Results: Our data from 32 monkeys (8 in each group) show 1. A significant global decrease in SERT binding in PR compared to MR monkeys, and 2. SERT binding is reversed in PR monkeys that received fluoxetine treatment.
Conclusions: Our study demonstrates serotoninergic alterations in PR monkeys, and chronic fluoxetine treatment may reverse deficits in SERT density that is persistent more than one year after medication discontinuation.
PET with the radioligand [carbonyl-11C]WAY-100635. 5-HT1A binding potentials (BPND) were quantified using the Logan non-invasive model with cerebellar gray matter (excl. vermis) as reference in PMOD3.3. 5-HT1A autoreceptor binding was estimated with a 4 mm spherical region-of-interest placed manually in the dorsal raphe nucleus. Voxelwise BPND maps were computed to assess local 5-HT1A heteroreceptor binding in projection areas. The DMN was calculated by functional connectivity analysis from a 6 min resting-state fMRI scan in Matlab/SPM8. Preprocessing included regression against white matter, ventricular and global signal, movement parameters and bandpass filtering (0.007 < f < 0.08 Hz). To avoid seed selection bias, the BOLD signal was averaged across the entire network (intersection of group maps from seeds in posterior cingulate (PCC) and medial prefrontal cortices (mPFC), p < 0.05 FWE-corrected) followed by whole-brain cross-correlation and z-transformation. Associations between serotonin-1A bindings and the DMN were assessed by voxel-wise linear regression analysis with the biological parametric mapping toolbox. Entering both 5-HT1A dorsal raphe autoreceptor and local heteroreceptor binding into the model enables an evaluation of the two variables as independent predictors of DMN activity (i.e., adjusting for regional heteroreceptor binding when interpreting 5-HT1A autoinhibition and vice versa). Results: For local 5-HT1A heteroreceptors we found a positive modulation of the DMN in the retrosplenial cortex (RSC, r = 0.8, p < 0.05 FWE-corrected) and a negative association in the dorsal mPFC (r = -0.67, p < 0.001 uncorrected). In contrast, both 5-HT1A auto-and heteroreceptor binding predicted individual DMN activity in the PCC but in an inverse manner (r = 0.74, p < 0.05 FWE-corrected and r = -0.66, p < 0.001 uncorrected, respectively; see Figure) .
Conclusions: This work demonstrates a distinctive 5-HT1A regulation of various DMN regions, which are involved in episodic memory processing (RSC), self-referential judgements (dmPFC) and the evaluation of personal significance of events (PCC). Moreover, the inverse DMN modulation of dorsal raphe autoreceptors and local heteroreceptors in the PCC (the strongest hub in the human brain) suggests a well-balanced interaction between local and autoinhibitory 5-HT1A effects. 5-HT1A autoreceptors attenuate raphe cell firing, leading to reduced serotonin release at projection sites [2] . This decreases local 5-HT1A inhibition onto downstream glutamate neurons, which in turn increases the BOLD signal [1] .
Together with previous findings this study indicates a modulation of brain networks by complex distribution of neuronal receptors including expression sites on downstream glutamate and GABA neurons [3] .
Background: A popular alternative approach to full kinetic modeling is the so-called ''graphical approach'' [1] which is based on the approximate linear relationship between transformations of the plasma and brain concentration functions and for which the volume of distribution VT is equal to the slope of the relationship. This approximation improves as time t increases, and thus it is necessary to choose some cutoff time point t*, i.e., the graphical approach will consider only those points for which t > t*. If t* is chosen to be too small, the approximation is poor and therefore the estimate of VT will be biased. Conversely, if t* is chosen to be too large, the variance of VT will be higher because too few points are used in fitting. In such a graphical approach, it is common to select the value of t* based on visual inspection of a plot the transformed data. While this may be appropriate in low-noise situations, it is subjective and would not be practical when fitting many timeactivity curves. Though some automatic procedures for choosing t* are in use (as in PMOD), some specification of an arbitrary threshold (e.g., a bound on the limit of the relative size of residuals) is required. Methods: We propose an alternative completely automatic approach that is based on how well the graphical model fits the data. For each candidate t* value, we fit the data points corresponding to t > t* according to a likelihood-based procedure for graphical analysis [2] and calculate an estimate of the noise level. When considering candidate cutoff times greater than the true t*, these variance estimates will have a common mean, but for a candidate cutoff less than the true t*, these estimates will be biased upwards, with the bias increasing as the candidate t* value decreases.
Results: An automatic procedure for choosing the optimal t* based on this sequence of noise level estimates results from casting the problem as a problem in change-point estimation. In particular, we will estimate t* by applying an onset-of-trend changepoint model [3] to the estimates of the noise level. Results: Simulations showed DBP ND to be highly dependent on duration of data used to determine BP ND in the activation state. This was true for all DA signals tested. The pattern of DBP ND mirrored the shape of the DA signal. DBP ND tended to peak 10 min after DA take-off. A similar pattern was seen in the human data. No such pattern of DBP ND dependence on duration of data was apparent in simulations where DA was held constant.
Conclusions: The dependence of DBP ND , as estimated by SRTM, Logan, and equilibrium methods, on the duration of data analyzed illustrates the inability of these conventional methods to reliably quantify short-lived increases in endogenous DA. More complicated models which take into account timevariation in DA are needed to properly measure the effect of stimulus-induced DA release when the DA response is brief.
O27. Validation of the partial saturation approach for in vivo quantification of striatal dopamine D2 receptors with [ 11 C]raclopride Background: [ 11 C]Raclopride is a commonly used radiotracer for the in vivo quantification of Dopamine D2 receptor binding. The partial saturation approach (PSA) has been proposed to assess the appBmax and appKd in a single injection protocol [1] . Previously this method was successfully adapted for a range of receptor occupancy levels in healthy animals [2] . Fischer et al. [3] conducted a series of experiments measuring pharmacologically induced changes of synaptic DA concentrations in wild type and two transgenic mouse models. The aim of this study was to confirm that the PSA also produces stable and accurate parameter estimates in pharmacological or disease-induced changes in appBmax and appKd for [ 11 C]raclopride in the rodent. Method: The PSA uses the general equilibrium equation (B/F = (Bmax-B)/KdVr -dB/dT * (1/koff*F)) which includes a residual term as an indicator of the dynamic equilibrium state. For the dynamic equilibrium assumption to be met, the residual term should be within a certain small value [2] . Simulations: A series of partial saturation experiments with noise level equivalent to that of the PET (100 noise simulations per experiment) were simulated over a range of receptor occupancies for three appBmax levels and three appKd levels (normal, double and half) to mimic the expected levels in the experiments by Fischer et al. [3] : (i) 12 mice underwent one scan at baseline and one under challenge conditions (AMPH or Methylphenidate) (ii) two mouse models (n = 15) of human disease (Parkinson's and Huntington's disease). The parameters appBmax and appK d were estimated for each simulated experiment using the equilibrium relation for (i) a time window driven by constraining the residual term and (ii) a static time window of 10-50 mins. Results: Simulations: Figure 1 shows the difference between the appBmax estimates and the true Bmax for 4 of the simulations, high and low appBmax and appKd and for all occupancies with a fixed and guided time window. The improvement in accuracy when using the guided window seen in the appBmax estimates is echoed in the appKd estimate (not shown) and the improvement in accuracy can be seen in all appBmax/appKd levels simulated (not shown) with mean values that sit within 5-10% of the true appBmax/appKd values at occupancy levels > 50% and within 15% at occupancy levels of 30&40%. Experimental data: Please refer to the abstract by Fischer et al. for the results of the experimental data [3] . Conclusions: Our results demonstrate that the PSA with a guided time window produces accurate and stable estimates where large variations of appBmax and appKd are expected. The method is promising for assessing changes in appBmax and appKd after pharmacological interventions and in models of neurodegenerative disorders. neck. After 4-6 weeks of recovery in the baseline OFF condition and 30 minutes in the acute ON condition with 1.0 mA stimulation, dynamic PET began at injection of high specific activity ( > 50 GBq/mmol) [ 11 C]yohimbine with multiple frames increasing in length until 90 min. In the tests of amphetamine, animals received standard doses of 2 or 10 mg/kg d-amphetamine i.v. 20 minutes before the second [ 11 C]yohimbine PET. We obtained the total volume of distribution (V T ) for each region with the Logan graphical analysis during the 25-90-min post-[ 11 C]yohimbine injection period with an arterial input function. Results: As illustrated in the four panels of the Figure (groups 1-4 , clockwise from upper left panel), exogenous competitors occupied from 55% to 80% of the alpha-2 adrenoceptors with a V ND estimate of 1.6 ml/g. In the first amphetamine challenge with 10 mg/kg amphetamine, the putative endogenous ligand(s) occupied from 55% to 70% of the receptors, and in the second challenge with 2 and 10 mg/kg, from 35% to 40%. The non-displaceable volumes averaged 1.9 to 2.0 ml/g. With the average value of 1.8 ml/g, the acute vagal nerve stimulation led to an average saturation of 19% of the receptors. Conclusions: The inhibition plot is the simplest approach to the determination of binding potentials and saturability of neuroreceptors, when reference regions are not available, i.e., areas of the brain with no displaceable binding of the ligand. With volumes of distribution of 2-4 ml/g in Landrace pigs, and 3-6 ml/g in minipigs, corresponding binding potentials range from 0.1 to 1 in landrace pigs and 0.5 to 2 in minipigs. Development and validation of non-invasive detection methods for Ab plaques in the human brain would allow for a presymptomatic diagnosis and early preventive treatments. In addition to clinical applications, the successful establishment of in vivo Ab plaques detection in brains of mouse models of AD will be a powerful step in the development of new therapeutic treatments and markers of its efficacy. Importantly, using the same tracers in human and mouse studies would allow for the correlation of imaging data with the morphological and immunohistochemical data from animal studies. One of the most successful noninvasive techniques so far to visualize Ab plaques in patients with AD is PET imaging with C 11 -PIB tracer. However, in addition to C 11 -PIB's short half-life, the limitations of this tracer include a low sensitivity to Ab plaques in brains of AD mouse models. In this study, we tested a reliability of microPET in mice using F 18 -Florbetapir tracer. We hypothesize that by virtue of its longer half-life, F 18 -Florbetapir tracer can provide more favorable conditions to meet the requirement of high specific activity to Ab that is difficult to achieve with C 11 -PIB tracer. In the case of 11 C-PIB tracer, Maeda and colleagues (2007) had suggested that this tracer is particularly sensitive to such specific Ab subtypes as N-terminally truncated and modified Ab, AbN3-pyroglutamate. This type of amino-terminal modifications is a major component of human plaques (Saido et al., 1995) and is likely related to proteolytic activities of a number of proteases taking place over prolonged time (Iwata et al., 2005) . In AD patients, the percentage of truncated and modified amino-terminus has been shown to increase at the expense of full length Ab and is directly correlated with AD progression (Gü ntert et al., 2006) . In APP transgenic mice, the occurrence of N-terminally truncated Ab species was demonstrated to be decreased in comparison with human AD cases (Kuo et al., 2001; Rü fenacht et al., 2005) . These findings imply that the detectability of Ab amyloid by 11 C-PIB PET can differ in Alzheimer's disease (AD) and Tg mouse brains due to differential presence of modified Ab species (Kuo et al., 2001; Kawarabayshi et al., 2001; Gü ntert et al., 2006) . Methods: Thus, in this study, we tested a hypothesis that mouse models of AD with fast rate of amyloid plaque deposition yield lower F 18 -Florbetapir PET signal than models with slow accumulation. To this end, we compared two AD models, TetOffAPP Line 107 and PrP APPPS1 Line 85, with high and low rates, respectively. Results: PrP APPPS1 Line 85 mice had a significantly higher signal in cortex, hippocampus and other forebrain structures supporting our hypothesis. Conclusions: These studies validate the use of F 18 -Florbetapir for the visualization of mouse amyloid by PET imaging and open a new avenue for a wide use of this tracer in monitoring the dynamics of amyloid deposition in living brains of AD mice. amyloid load on a region-by-region basis for individuals who exhibited a range of amyloid load levels. Methods: Dynamic [ 11 C]PiB (or PiB) PET imaging was performed for 6 subjects (S) over 90 min (n = 5) or 60 min (n = 1). Scanning occurred within a 42 month (mos) interval (INT) before death for patients with Alzheimer's disease (AD) and dementia with Lewy bodies (DLB): 1) AD (63 yrs, INT = 10 mos); 2) AD (58 yrs; INT = 42 mos); 3) DLB (77 yrs, INT = 18 mos); 4) AD (54 yrs, INT = 30 mos); 5) AD (74 yrs, INT = 11 mos); 6) AD (80 yrs, INT = 37 mos). PiB retention was measured using the reference Logan DVR (DVR60, n = 6), standardized uptake value ratio (SUVR60: 40-60 min, n = 6), and 90 min simplified reference tissue model DVR (SRTM2 DVR, n = 5), with cerebellum as reference region. Post-mortem Ab plaque load was assessed by applying Ab immunohistochemistry (4G8) and a highly fluorescent derivative of PiB (6-CN-PiB) to 12 mm paraffin sections of multiple cortical and subcortical regions-of-interest (ROIs). A ROI-labeled autopsy image guided ROI generation on the ante-mortem MR and sampling of the coregistered PET data. ROIs included key cortical gray matter rich areas (e.g., frontal cortex, FRC) and a white matter rich area (internal capsule). PiB data were corrected for atrophy-related CSF dilution. Although limited by sample size, relationships were examined using Pearson correlation. Results: The frontal PiB DVR60 values were: 2.7 (S1), 2.0 (S2), 1.1 (S3), 1.4 (S4), 2.2 (S5), and 1.8 (S6).
Relative consistency was observed for the 6-CN-PiB and 4G8 measures for each subject with higher loads for S1, S2 and S5 than for S3, S4, and S6; and this was consistent across all types of retention outcomes. Stronger relationships were observed between PiB and 6-CN-PiB than for 4G8. For the FRC, DVR60 comparisons yielded: y = 0.12x + 1.22, R = 0.96 (6-CN-PiB) and y = 0.08x + 1.42, R = 0.67 (4G8), while SUVR60 comparisons yielded: y = 0.17x + 1.47, R = 0.95 (6-CN-PiB) and y = 0.13x + 1.65, R = 0.76 (4G8). The absence of Ab plaques and 6-CN-PiB labeling in postmortem tissues corresponded to PiB DVR60 values between 1.0-1.2. In white matter rich areas, the null-signal for postmortem outcomes coincided with PiB DVR values from 1.3-1.6 (Logan and SRTM2). . The objective of this study was to assess the impact of flow variations on the measurement of longitudinal changes in specific [ 11 C]PIB binding derived from reference tissue based methods. Methods: Two simulations were performed, one assuming different changes in flow in target (global cortical region) and reference regions (i.e. a change in R 1 ) at follow-up and another assuming the same change in flow in both regions (global flow change). Furthermore, it was assumed that BP ND did not change at follow-up. Simulations were based on typical [ 11 C]PIB plasma input curves, microparameters and blood volume fractions obtained from dynamic 90 min PET studies of Alzheimer's disease (AD) patients. For both simulations SUV ratios (SUVr) were calculated for several uptake times (ranging from 30 to 90 min p.i.). For comparison, BP ND + 1 was obtained using a basis function implementation of SRTM (RPM) based on the simulated 90 min reference and cortical time-activity curves. For both SUVr and BP ND + 1, percent bias compared with 'true' (simulated) BPnd + 1 values was calculated. In addition, artificial percent change in SUVr or BPnd + 1 as a result of global or heterogeneous flow change are evaluated. Results: Simulations revealed that SUVr values were highly dependent on uptake period, with biases of up to + 25%. Moreover, longitudinal changes in both K 1 (global flow changes) or R1 (differential flow changes) induced both positive and negative artificial changes in [ 11 C]PIB binding estimates based on SUVr of up to 10%. Biases in BP ND + 1 were much smaller ( < 5%) in all cases. These differences in flow induced changes in SUVr and BP ND + 1 were in line with differences in SUVr and BP ND + 1 changes seen in longitudinal studies in AD patients, suggesting that flow effects may play a role in the latter studies. Conclusions: Choosing the right method for quantitative assessment of longitudinal changes in [ 11 C]PIB binding is of the utmost importance in the case of global or regional flow changes over time or as a result of treatment. For monitoring effects of novel anti-amyloid drugs, specific binding of [ 11 C]PIB should be determined using full kinetic analysis in combination with dynamic PET scans.
O32. Combined CBF and binding analyses with single 11 C-PIB PET session in Alzheimer's disease and healthy controls Background: The 11 C-labeled Pittsburg Compound B (PIB) is a tracer of A-beta plaque load used to diagnose Alzheimer's disease (AD). However, the rapid initial clearance of the tracer from the blood stream mimics the kinetic behavior of a microsphere with a very rapid distribution to the tissue, followed by washout that is almost solely governed by the flow-mediated clearance from the tissue. Previous studies used either Logan linearization (LL) for parametric mapping of the distribution volume (DV), or simple computation of a ratio measure (RM) of steady-state accumulation relative to a reference region such as the pons or cerebellum gray matter, using area-under-curve (AUC) values of late time (60-90 minutes). These methods are known to be clearly influenced by flow, and existing studies suggest that the high retention in white matter is largely attributable to slow PIB kinetics, while the opposite is true for putamen and other high flow areas. Paradoxically, the high accumulation in low flow areas potentially makes the methods more valuable to the diagnosis of AD because cortical flow rates consistently are lower in AD than in healthy control subjects. Here, we used a novel analysis of both flow-delivery and delayed washout by binding to obtain separate estimates of flow and binding. Methods: We analyzed the difference, magnitude and distribution of the flow and binding components, and we compared the use of flow-normalized reference curves in the LL and RM methods to the flow independent HYPOTIME method for the ima-ging of the PIB-retention. The HYPOTIME method identified potential non-binding reference tissue directly from the data. Both healthy aged controls (HC) and patients with AD were tested with 11 CPIB and 15 O-water (for CBF validation). Results: The initial wash-in peak value of the PIB signal relative to the reference region (R1 signal) correlated well with the gold standard R1 signal from 15 O-water. The R1 signal from PIB therefore served as a surrogate measure of the real R1. By normalizing PIB-derived R1 to injected dose and patient weight as well as calibration to a site specific factor, we obtained a surrogate measure of absolute CBF. Using the PIB derived R1, images were quantified in terms of binding potential and rate constants for the radiotracers before and after flow normalization using the LL, RM, and flow independent HYPOTIME methods. The flow difference between the AD and HC groups contributed significantly to the difference between the groups, with highly significant (P = 0.0018) reduction of cortical CBF in AD compared to HC subjects. This difference was independent of the use of the real or the surrogate CBF measure derived from the PIB scan. Conclusions: This work shows that CBF is likely to confound any PIB-binding differences between the groups if not properly accounted for. The method also presents a simple estimate of relative (R1) and absolute (CBF) blood flow, directly from a single dynamic PIB session, by separation of specific binding from the flow-derived retention.
